SEPMAG sees 400% US revenue growth based on biomagnetic separation
7 March 2011
SEPMAG, a manufacturer of biomagnetic separation systems for
the in vitro diagnostics (IVD) market, has forecast that it is set to
again outperform challenging economic conditions, secure high revenues
growth and to further cement its foothold in the US IVD market.
The announcement comes on the back of its 2010 results which saw
sales grow by 89% globally and 112% within the US. Already this
year, the Company has begun shipping to leading IVD companies across
the USA including Biocontrol, Innova and Abi Life Tech.
Josep Maria Simó, CEO of SEPMAG, commented: “2010 has been
another stellar year for SEPMAG and we have rapidly established a
growing foothold across the USA — the largest worldwide market — and
just a year after opening our Atlanta offices. We have found the US
market to be highly receptive to new technologies and we are already
seeing a number of IVD companies moving from straight magnets to our
homogeneous systems that provide more consistent results”
SEPMAG’s precision magnetophoresis systems, unlike other
biomagnetic separation processes, produce a completely homogeneous
magnetic field, which applies the same magnetic force on beads
regardless of the distance from the magnetic ring.
Using conventional separators, beads that are further away from
the magnet are harder to manipulate and those that are closer may
experience an excessive force, often resulting in bead aggregation,
loss of activity and resuspension problems. In contrast, SEPMAG’S
unique magnet alignment vastly reduces the variability of the end
product, enables a more straightforward scale-up process and greatly
simplifies revalidation processes.
Josep, continued: “We confidently predict that our rapid
expansion into the US will continue throughout 2011 with record
growth at a rate of nearly 400% this year, outperforming the
percentage growth forecast for companies operating in the IVD
market. Our success is built primarily on our novel, patented
biomagnetic separation technology that produces better results than
other technologies available to US diagnostic manufacturing
companies. We envisage that this exponential growth will be achieved
as knowledge of our offerings spread across the US IVD market”.